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Abstract
Background: Atrial fibrillation is the most common cardiac arrhythmia. It is responsible for up to 20% of all
ischemic strokes. Rate control and anticoagulation are crucial for atrial fibrillation management and stroke
prevention.
Case presentation: We present the case of an 84-year-old Italian woman with a left atrial appendage thrombus
that developed despite her use of anticoagulant therapy with warfarin for a previous pulmonary embolism. She had
atrial fibrillation and heterozygosity for both factor V Leiden and methylenetetrahydrofolate reductase C677T
mutation, thus creating resistance to activated protein C. Anticoagulant therapy was switched to heparin for 1 week
and then to rivaroxaban. After 3 months of rivaroxaban use, the thrombus disappeared.
Conclusions: This case raises the issue of the ineffectiveness of warfarin therapy in complex cases involving
particular thrombophilic conditions and the possibility of using rivaroxaban as a safe and effective alternative.
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Background
Atrial fibrillation (AF) is the most common cardiac
arrhythmia. Its clinical presentation spans from asymp-
tomatic AF to cardiogenic shock or devastating cerebro-
vascular accident. It is responsible for up to 20% of all
ischemic strokes [1]. The cornerstones of AF management
are rate control and anticoagulation [2]. However, anticoa-
gulation can be trivial in patients with some types of
thrombophilias. Thrombophilias are inherited and
acquired hypercoagulable conditions that increase the risk
of thromboembolism and, in some cases, can lead to
resistance to warfarin anticoagulant therapy [3, 4]. Direct
oral anticoagulants (DOACs) are now available and can be
considered alternatives to warfarin for patients with non-
valvular AF [2]. Among these, rivaroxaban, an oral factor
Xa inhibitor, provides more consistent and predictable
anticoagulation than warfarin [5, 6].
Here, we present the case of a woman with AF and
thrombophilia who developed a left atrial appendage
(LAA) thrombus while on warfarin therapy and was sub-
sequently treated with rivaroxaban.
Case presentation
An 84-year-old Italian woman presented to our hospital
with a stroke and was referred to our cardiology unit for
cardiologic evaluation. She had a history of hyperten-
sion, dyslipidemia, and pulmonary embolism and was
using warfarin for pulmonary embolism during our
evaluation: international normalized ratio (INR) 2.3; time
in therapeutic range (TTR) >63%. She reported palpita-
tions and dyspnea that started 1 week before our evalu-
ation. An electrocardiogram showed AF with a heart
rate of 96 beats per minute. Transthoracic echocardiog-
raphy revealed normal left ventricle (LV) diameters and
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volume, left ventricular ejection fraction of approximately
60%, and a dilated left atrium (LA) with dense spontan-
eous echo contrast. Transesophageal echocardiography
(TEE) showed a round, partially mobile, disorganized and
weakly hypoechogenic mass (12 × 12 mm) that resembled
a thrombus in the LAA (Fig. 1a). We examined the follow-
ing in regard to thrombophilia: prothrombin time, acti-
vated partial thromboplastin time, fibrinogen, activated
protein C resistance, factor V Leiden, prothrombin
G20210A mutation, homocysteine, ATIII, protein C, pro-
tein S, antiphospholipid antibodies (lupus-like anticoagu-
lant), anti-beta 2 glycoprotein I antibodies, anti-cardiolipin
antibodies, factor VIII, and methylenetetrahydrofolate re-
ductase C677T mutation. Testing revealed heterozygosity
for both factor V Leiden and methylenetetrahydrofolate
reductase C677T mutation, which created resistance to
activated protein C [7].
We started anticoagulant treatment with unfractio-
nated heparin administered intravenously. After 1 week
of therapy, we performed a second TEE that showed that
the LAA thrombus remained unchanged (Fig. 1b). Her
treatment was then switched to rivaroxaban 20 mg once
daily for long-term treatment and stroke prevention [8].
A third TEE performed at the 3-month follow-up visit
revealed no thrombotic mass (Fig. 1c). No major or clin-
ically relevant bleeding occurred during follow-up. At
the 6-month and 12-month follow-up visits, she contin-
ued to be in good clinical condition. After thrombus
resolution, because our patient was at high risk for
thromboembolism and had a history of pulmonary em-
bolism, we recommended LAA percutaneous occlusion;
however, she refused this option.
For rate control, because our patient had a first diag-
nosed AF with mean ventricular response, we treated
her with a beta blocker (bisoprolol) at low dosages (1.25
mg twice daily).
Discussion
Thrombophilias are conditions that continue to create
controversy for care providers. The case analyzed
Fig. 1 a Transesophageal echocardiography at diagnosis showing a mass in the left atrial appendage. b Transesophageal echocardiography after 7
days of treatment with intravenous unfractionated heparin showing a mass in the left atrial appendage. c Transesophageal echocardiography after 3
months of rivaroxaban use showing no visible mass in the left atrial appendage. d Doppler with high-speed blood flow in the appendage after 3
months of rivaroxaban use
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emphasizes the role of inherited thrombophilic factors
in creating high risk for thromboembolism [9]. The pa-
tient described here had a thrombus in the LAA that de-
veloped despite treatment with warfarin. Two factors
may have favored this: the combination of thrombophilic
factors and the suboptimal TTR.
The combination of thrombophilic factors may
explain, in part, the poor anticoagulant response to
warfarin and the failure to reduce the LAA thrombus
with heparin [1]. Heterozygosity for both factor V Lei-
den and methylenetetrahydrofolate reductase C677T
mutation and resistance to activated protein C (a natural
anticoagulant) may have created, in this particular pa-
tient with nonvalvular AF, resistance to warfarin therapy.
Factor V Leiden mutation induces the resistance of fac-
tor V to cleavage by activated protein C [10]. The en-
zyme 5,10-methylenetetrahydrofolate reductase is
involved in folate metabolism and its C677T polymorph-
ism is associated with increased plasma homocysteine
levels if the dietary folate intake is insufficient [11]. High
plasma levels of homocysteine increase the risk of
thrombosis by enhancing factor V activity [11]. It may
be possible that, in this patient, enhanced activity of fac-
tor V combined with resistance to protein C may have
favored the paradoxical procoagulant effect of warfarin
as opposed to its therapeutic anticoagulant effect. War-
farin, as a vitamin K antagonist (VKA), acts indirectly on
a number of coagulation factors and also on protein C,
which has an important anticoagulant role in the modu-
lation of coagulation [12].
On the other hand, warfarin may also not have pro-
vided a continuous anticoagulant effect [13]. Our patient
had a TTR more than 63%, which should be improved
especially considering the presence of more thrombophi-
lic factors. The 2016 European Society of Cardiology
guidelines recommend a target TTR ≥70% for patients
with AF using warfarin; however, if this cannot be
reached, then switching to a DOAC should be consid-
ered [2]. In this regard, and considering that the patient
could not undergo percutaneous LAA occlusion, a pro-
cedure that could have lowered the risk of cardioembolic
stroke [14], we decided to switch the anticoagulant ther-
apy from warfarin to heparin for 1 week and then, for
long-term therapy, to rivaroxaban, a DOAC with once-
daily dosing approved for stroke prevention in patients
with nonvalvular AF at high risk [15].
Cardioembolic stroke is the most serious problem in the
aging population [16]. The rate of ischemic stroke in pa-
tients with nonrheumatic AF is approximately 5% per year.
We cannot explain the reason for the effectiveness of rivar-
oxaban compared to warfarin. However, in this patient, riv-
aroxaban was effective not only for preventing thrombus
formation but also for favoring thrombus resolution when
warfarin treatment had failed [4, 17]. Optimal compliance,
direct action on factor Xa, and the predictable pharmaco-
dynamics and pharmacokinetics of rivaroxaban may have
favored this higher efficacy [15].
The recently published X-TRA study, which is the first
prospective, multicenter, interventional study to examine
thrombus resolution with a DOAC in VKA-naïve
patients or patients receiving suboptimal or ineffective
VKA therapy (INR <2.0), showed that resolved or
reduced thrombus after rivaroxaban treatment is consist-
ent with LA/LAA thrombus resolution with VKA ther-
apy reported in retrospective observational case series
[18]. These results suggest that rivaroxaban may be an
option for the treatment of TEE-detected LA/LAA
thrombi in patients with AF or atrial flutter. It is note-
worthy that in the X-TRA population, at baseline,
approximately three-quarters of patients had persistent,
long-standing, or permanent AF. This reflects a gap
between guideline recommendations and local practice
and indicates that patients diagnosed with AF are not
adequately treated with an oral anticoagulant.
Conclusions
This case raises the issue of the ineffectiveness of war-
farin therapy for complex cases involving particular
thrombophilic conditions and of the possibility of using
rivaroxaban as a safe and effective alternative. Further
investigations of the effects of the different types of anti-
coagulants in particular subgroups of patients with AF
and inherited thrombophilias are needed to gain a better
understanding of the mechanisms that can cause the
ineffectiveness of VKA treatments and that can help
physicians choose the best DOAC.
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